Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,195.31 +14.57 (+0.28%) Dow
38,934.72 +82.45 (+0.21%) Nasdaq
16,383.98 +34.73 (+0.21%) Bitcoin USD
63,796.45 +477.04 (+0.75%) CMC Crypto 200
1,330.29 -34.84 (-2.55%)
VRTX Jan 2025 440.000 call
| Previous close | 26.24 |
| Open | 25.90 |
| Bid | 26.20 |
| Ask | 27.80 |
| Strike | 440.00 |
| Expiry date | 2025-01-17 |
| Day's range | 25.90 - 26.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 415 |
- Thomson Reuters StreetEvents
Q1 2024 Vertex Pharmaceuticals Inc Earnings Call
Q1 2024 Vertex Pharmaceuticals Inc Earnings Call
- GuruFocus.com
Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
Discover how Vertex Pharmaceuticals Inc achieved significant financial and operational milestones in the first quarter of 2024.
- Reuters
UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
